Cessatech A/S Logo

Cessatech A/S

Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.

CESSA | SPGR

Overview

Corporate Details

ISIN(s):
DK0061411964
LEI:
549300WO5SKVXWPOXR16
Country:
Denmark
Address:
Kanonbådsvej 2, 1437 København K
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cessatech A/S is a pharmaceutical company specializing in the development and commercialization of evidence-based medicines for children. The company focuses on addressing unmet needs in pediatric care, particularly the treatment of acute pain. Its lead asset, CT001, is a non-invasive analgesic nasal spray for children aged 1-17 undergoing painful medical procedures. This product is designed as an alternative to traditional pain management solutions, such as intravenous injections, which can be distressing for young patients. Originating as a spinout project from Rigshospitalet, Cessatech's business model centers on developing drugs with a potentially shortened time-to-market. The management team has a proven track record in drug development, paediatric research, and global product launches.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cessatech A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cessatech A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cessatech A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.